Clinical trials: Advanced Pancreatic Ductal Adenocarcinoma
Solid Tumor, Adult, Colorectal Cancer
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2b.
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06598007
- Testing
- CT3001, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Crossignal Therapeutics, Inc.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05983133
- Testing
- PF-08046052
- Where
- 24 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Non-Small Cell Lung Cancer, Ovarian Cancer
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express…
- Conditions
- Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04025216
- Testing
- CART-TnMUC1, Cyclophosphamide, Fludarabine
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Pancreatic Ductal Adenocarcinoma
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and…
- Trial name
- NCT05257993
- Testing
- JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
- Where
- 4 sites in South Korea
- Volunteers
- 71 people
- Sponsor
- Onconic Therapeutics Inc.
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma
This will be a single-arm, multi-center, open-label phase 1 study. The standard 3+3 design will be used to determine the maximum tolerated dose (MTD) from 4 possible dose levels of Eryaspase in combination with mFOLFIRINOX.
- Trial name
- NCT04292743
- Testing
- Eryaspase, FOLFIRINOX
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Georgetown University
Pancreas Cancer, Pancreatic Adenocarcinoma
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma…
- Conditions
- Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- SEPION (NCT04257448)
- Testing
- Romidepsin, Azacitidine, nab-Paclitaxel
- Where
- 9 sites in Germany
- Volunteers
- 75 people
- Sponsor
- GWT-TUD GmbH
Advanced Pancreatic Ductal Adenocarcinoma
KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.
This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with…
- Trial name
- NCT05149326
- Testing
- KN046
- Where
- 65 sites in China
- Volunteers
- 408 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd